Alzheimer's disease: perspectives for the new millennium
about
Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patientsEstablishing Natural Nootropics: Recent Molecular Enhancement Influenced by Natural NootropicThe cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activityCysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeuticsGenetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor proteinCysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's diseaseClusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's diseaseMechanisms underlying basal and learning-related intrinsic excitability in a mouse model of Alzheimer's disease.Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice.Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease.Amyloid-beta immunotherapy for Alzheimer's diseaseInhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761.Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's diseaseResorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy.Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid.Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation.Unique neuronal functions of cathepsin L and cathepsin B in secretory vesicles: biosynthesis of peptides in neurotransmission and neurodegenerative disease.Nucleolar PARP-1 Expression Is Decreased in Alzheimer's Disease: Consequences for Epigenetic Regulation of rDNA and Cognition.Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibitionAlternative pathways for production of beta-amyloid peptides of Alzheimer's disease.Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters.Fish-on-a-chip: a sensitive detection microfluidic system for Alzheimer's disease.Plants traditionally used in age-related brain disorders (dementia): an ethanopharmacological survey.Genetic studies in Alzheimer's disease.Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease?Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice.Cathepsin L expression is directed to secretory vesicles for enkephalin neuropeptide biosynthesis and secretion.Serum tumour necrosis factor-α and interleukin-6 levels in Alzheimer's disease and mild cognitive impairment.
P2860
Q24633400-DF5BDE48-3A5B-401F-9628-B35EEAC786E4Q28071703-861668E7-607C-40C0-8C48-E841C0B53245Q28238581-876902E8-70D9-42C8-9A0D-4DC5600A8F27Q28240590-A9D55FFE-16E0-4074-BE41-696556681029Q28247574-63EB7787-C7D2-45C4-BE1C-A2BC5903C1A8Q28285644-3E18F2A5-5564-4052-B060-5B3784345A45Q28504767-AB247A8D-46F5-4CD7-A3B5-85D04664D880Q30494949-7B7B2736-6877-489D-A0CA-1C15AABFE26BQ30623665-B64D8370-0736-4D65-805B-E7CC21A4E7B6Q33289360-D2375FCB-F046-4453-8A02-3B55AB2BA6EAQ33954737-9F457996-2BAE-4EA0-AF08-C420CCAC7CBBQ34155629-1B0BDA15-8FD8-4D99-BB45-6AEB2417174CQ35596997-BA9BC052-EF4C-4F01-8475-406F7B92A566Q35674780-BCD093B3-24CD-4BC6-8DC2-942B592BABAAQ35748577-E9BCB8A9-B6D4-4C62-8C83-7D7BAE82BF0EQ36556213-F5CD7A8B-044D-46DE-BA49-A0552783231AQ36642766-3BE4BFB3-5074-4BE3-864F-636144B3BD85Q36681098-CD80473D-A7EB-4A6C-AFCD-DF467D64B051Q37061721-4C38F1AF-845C-4FCD-8341-853C696BA8D9Q37124928-6DD6E25A-8453-4B3E-9C32-023A86C016E4Q37346926-2DA5D6F5-A461-4478-B394-B4A619AFF556Q37880972-E4B03BED-7487-4DD3-BCF3-5BE7E9205048Q38075593-295764C4-3813-4899-9036-C3B3C7D64E08Q38579624-F6C5DC1E-FB9E-4CD2-8B5C-C3C352D5B020Q39909606-D19170AB-82B4-4FD0-8AF4-47DC986FA35FQ40909568-9C092034-A603-4162-90CB-D1E91171DE6EQ44754448-FF2108CD-057F-4274-BC09-4387BA525C4BQ47815645-345B947C-5999-4818-B94B-C60093C78133
P2860
Alzheimer's disease: perspectives for the new millennium
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Alzheimer's disease: perspectives for the new millennium
@ast
Alzheimer's disease: perspectives for the new millennium
@en
type
label
Alzheimer's disease: perspectives for the new millennium
@ast
Alzheimer's disease: perspectives for the new millennium
@en
prefLabel
Alzheimer's disease: perspectives for the new millennium
@ast
Alzheimer's disease: perspectives for the new millennium
@en
P356
P1476
Alzheimer's disease: perspectives for the new millennium
@en
P2093
Sisodia SS
P304
P356
10.1172/JCI8508
P407
P577
1999-11-01T00:00:00Z